MELBOURNE, Australia and INDIANAPOLIS, June  23, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, &#34;Telix&#34;) today announces an educational webinar exploring the unmet needs in

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

Telix Hosts Neurologic Oncology Webinar Highlighting Theranostics Potential

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MELBOURNE, Australia and INDIANAPOLIS, June  23, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, &amp;#34;Telix&amp;#34;) today announces an educational webinar exploring the unmet needs in</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Telix announced an educational webinar addressing unmet needs in neurologic oncology and theranostics, featuring CMO David Cade and a panel from UMC Utrecht and Kepler University Hospital Linz. The June 29/30, 2026 event includes a clinical update and Q&amp;A with Telix leadership, signaling continued focus on radiopharmaceuticals for glioma and glioblastoma. Expect modest near-term stock impact unless new data or partnerships are disclosed.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Telix to host webinar on unmet needs in neurologic oncology and theranostics.</li><li>CMO Cade to present; fireside chat with Utrecht and Linz neuro-oncology experts.</li><li>Webinar set for June 29 (ET) / June 30 (AEST); registration link provided.</li><li>Event highlights theranostics&#039; potential for glioma and glioblastoma treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Telix Pharmaceuticals Limited (TLX)</strong>: Announced educational webinar on neurologic oncology and theranostics.</li><li><strong>UMC Utrecht (N/A)</strong>: Academic medical center; panel participant in the webinar.</li><li><strong>Kepler University Hospital Linz (N/A)</strong>: Neuro-oncological center; panel participant in the webinar.</li><li><strong>Telix Therapeutics (N/A)</strong>: CEO Richard Valeix participates in the event; corporate relevance noted.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The release centers on a structured investor-education event rather than data or regulatory milestones, signaling ongoing corporate storytelling around Telix’s theranostics strategy.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>No immediate earnings or regulatory news accompanying the event.</li><li>Any data, partnerships, or disclosures could trigger short-term TLX moves.</li><li>Trading could be volatile around the webinar timing due to investor interest.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Telix is listed on ASX (TLX) and NASDAQ (TLX).</li><li>Webinar date/time: EDT June 29, 2026, 5:00 p.m.; AEST June 30, 2026, 7:00 a.m.</li><li>Speakers: David N. Cade, Nelleke Tolboom, Josef Pichler; Q&amp;A with Richard Valeix.</li><li>Topic: unmet needs in glioma/glioblastoma and theranostics.</li><li>Registration link provided in the announcement.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; potential upside if new data or partnerships are announced during the webinar.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">MELBOURNE, Australia and INDIANAPOLIS, June  23, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TLX">TLX</a>, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.</p>  <p align="justify">David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update, which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria).</p>  <p align="justify">The presentation will be followed by Q&amp;A with Dr. Cade and Richard Valeix, CEO, Telix Therapeutics.</p>  <p align="justify"><strong>Webinar date and time:</strong></p>  <p align="justify">EDT: Monday June 29, 2026, 5:00 p.m.</p>  <p align="justify">AEST: Tuesday June 30, 2026, 7:00 a.m.</p>  <p align="justify">Participants can register for the webinar at the following link: <br></br><a href="https://www.globenewswire.com/Tracker?data=reGy5hw7iHh19UXdsQlIozbgJjUyE0gOhN6V50nEHxF9wXKWEdwIzNZWMye3zJ3KpvpRSE5j49Qf6XuIsWkIXS6yY6IVMWtWHiM0v5PCaXoT29j5NnssrRLdy4QDsnHEUj6oymXrxLECPutamSiv_80H9k5w09trHmB-5eh4JkPlQIHrTebCxMnKh_fxglew" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10054826-mur5i9.html</a></p>  <p align="justify"><strong>About </strong><strong>Telix Pharmaceuticals Limited </strong></p>  <p align="justify">Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TLX">TLX</a>).</p>  <p align="justify">Visit <a href="https://www.globenewswire.com/Tracker?data=NK1F7QzPqrtjAuXYY4QiO2jlhBdS4-_8tGMYl6MXJGOgKX3whuKybQ_B94t_YJVhozJnDKsbcMaUdN8Jhzm_q8iUbpihTyIFHFiSXKGKBqg=" rel="nofollow" target="_blank">www.telixpharma.com</a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href="https://www.globenewswire.com/Tracker?data=ijZEI3K0l4BBa09teBKV7wtkBLJDuQhe6AU5fZKZt5qvpStGDkR-wALPOAdbJXktFVyqNNX0wfOeQAeUYRJhPcductdpkYaO7uTwKN-cwcNw1v_aRSMjh32dBE3JAV2u" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=XOZ8-raEV_-2diKzGfxBOewFVzr7RivSiJAkazsAkxBoEN3GwCJBDr6ZgrW0QgB-36AjXKbIbnLZYzM4BQg-RA==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=bQNSgYOb8JU6Rru6o6JK-ZSaM6DFPhomvSYe67nEdeDBjXqKjnG_gG7lc58-2zAFXmGndNRboWj3JwBLKgXRMfTL8KGCwW4JDj64PufdW5U=" rel="nofollow" target="_blank">Facebook</a>.</p>  <p align="center">Legal Notices</p>  <p align="center"><em>Cautionary Statement Regarding Forward-Looking Statements.  </em><br></br></p>  <p align="justify"><em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.</em></p>  <p align="justify"><em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.</em></p>  <p align="justify"><em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.</em></p>  <p align="justify"><em>Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the &#xAE; or &#x2122; symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.</em></p>  <p align="justify"><em>&#xA9;2026 Telix Pharmaceuticals Limited. All rights reserved.</em></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MDc2MCM3NjcxNzA3IzIwODMyNDI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODg1ZjQ3MTktYzA3Yi00ODI2LWE0YzQtMGE1MDVlZWY4ZmJkLTEwOTQ4MTMtMjAyNi0wNi0yMi1lbg==/tiny/Telix-Pharmaceuticals-Limited.png" referrerpolicy="no-referrer-when-downgrade"></img><pre>Telix Investor Relations (Global)

Ms. Kyahn Williamson
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com

Telix Investor Relations (Australia)

Ms. Charlene Jaw
Associate Director Investor Relations
charlene.jaw@telixpharma.com

Telix Investor Relations (U.S.) 

Ms. Annie Kasparian 
Director Investor Relations and Corporate Communications 
annie.kasparian@telixpharma.com</pre><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/77ceffdf-31cc-415f-9747-efee950af329"><img src="https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png" border="0" width="150" height="62" alt="Primary Logo"></img></a></p>

Telix announced an educational webinar addressing unmet needs in neurologic oncology and theranostics, featuring CMO David Cade and a panel from UMC Utrecht and Kepler University Hospital Linz. The June 29/30, 2026 event includes a clinical update and Q&A with Telix leadership, signaling continued focus on radiopharmaceuticals for glioma and glioblastoma. Expect modest near-term stock impact unless new data or partnerships are disclosed.

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News